Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading
Shares of ReNeuron Group Plc (LON: RENE) today surged 10.2% after the company announced that it had started extended phase IIa trials of its hRPC cell therapy for retinitis pigmentosa, a degenerative eye condition.
The company which specialises in stem-cell research today announced that it had started dosing procedures within the US and that the expanded phase IIa trial will include at least nine people who will receive higher doses of the hRPC cell therapy.
Ten patients are already participating in the study, which will raise the total number to nineteen patients, distributed across the UK and America. Further results will be published in the next 12 months.
The hRPC treatment has been granted orphan drug status in both the US and Europe with the US Food & Drug Administration (FDA) giving it fast-track status, which bodes well for the treatment.
ReNeuron share price
ReNeuron shares today surged 10.2% to trade at 99p having ended Wednesday’s session trading at 89.8p.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .